Published in Circ Res on September 03, 2010
Selective extracellular vesicle-mediated export of an overlapping set of microRNAs from multiple cell types. BMC Genomics (2012) 1.58
MicroRNAs in Human Diseases: From Cancer to Cardiovascular Disease. Immune Netw (2011) 1.29
miR-200b is involved in intestinal fibrosis of Crohn's disease. Int J Mol Med (2012) 1.09
MicroRNA-134 as a potential plasma biomarker for the diagnosis of acute pulmonary embolism. J Transl Med (2011) 1.01
Cross-mapping events in miRNAs reveal potential miRNA-mimics and evolutionary implications. PLoS One (2011) 0.93
Urinary microRNA-10a and microRNA-30d serve as novel, sensitive and specific biomarkers for kidney injury. PLoS One (2012) 0.92
MicroRNAs in Human Diseases: From Autoimmune Diseases to Skin, Psychiatric and Neurodegenerative Diseases. Immune Netw (2011) 0.90
microRNA-based diagnostics and therapy in cardiovascular disease-Summing up the facts. Cardiovasc Diagn Ther (2015) 0.89
miRNA-197 and miRNA-223 Predict Cardiovascular Death in a Cohort of Patients with Symptomatic Coronary Artery Disease. PLoS One (2015) 0.85
MicroRNA-27a decreases the level and efficiency of the LDL receptor and contributes to the dysregulation of cholesterol homeostasis. Atherosclerosis (2015) 0.81
Cardiac biomarkers in the intensive care unit. Ann Intensive Care (2012) 0.77
Integrated microRNA‑gene analysis of coronary artery disease based on miRNA and gene expression profiles. Mol Med Rep (2016) 0.75
Circulating microRNAs in patients with coronary artery disease. Circ Res (2010) 6.28
MicroRNA-133 controls cardiac hypertrophy. Nat Med (2007) 11.68
Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ Res (2004) 8.41
Adult c-kit(pos) cardiac stem cells are necessary and sufficient for functional cardiac regeneration and repair. Cell (2013) 4.99
ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med (2002) 3.36
Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc Natl Acad Sci U S A (2002) 3.18
MicroRNAs and cardiac pathology. Nat Rev Cardiol (2009) 2.50
Emerging role of microRNAs in cardiovascular biology. Circ Res (2007) 2.41
MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circ Res (2009) 2.40
Association of the FOXO3A locus with extreme longevity in a southern Italian centenarian study. Rejuvenation Res (2009) 2.24
Relation of various plasma growth factor levels in patients with stable angina pectoris and total occlusion of a coronary artery to the degree of coronary collaterals. Am J Cardiol (2005) 2.14
CaMK4 Gene Deletion Induces Hypertension. J Am Heart Assoc (2012) 2.14
Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. JACC Cardiovasc Interv (2013) 2.11
Akt mediates the cross-talk between beta-adrenergic and insulin receptors in neonatal cardiomyocytes. Circ Res (2004) 2.08
MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice. J Clin Invest (2010) 2.04
Deregulation of microRNA-503 contributes to diabetes mellitus-induced impairment of endothelial function and reparative angiogenesis after limb ischemia. Circulation (2011) 1.99
Reciprocal regulation of microRNA-1 and insulin-like growth factor-1 signal transduction cascade in cardiac and skeletal muscle in physiological and pathological conditions. Circulation (2009) 1.92
IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by direct phosphorylation. Proc Natl Acad Sci U S A (2011) 1.87
MicroRNAs: components of an integrated system controlling cardiac development, physiology, and disease pathogenesis. Cardiovasc Res (2008) 1.75
MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling. Nat Cell Biol (2010) 1.74
Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res (2013) 1.72
MicroRNA-133 controls vascular smooth muscle cell phenotypic switch in vitro and vascular remodeling in vivo. Circ Res (2011) 1.67
MicroRNA control of podosome formation in vascular smooth muscle cells in vivo and in vitro. J Cell Biol (2010) 1.64
Direct intramyocardial percutaneous delivery of autologous bone marrow in patients with refractory myocardial angina. Am Heart J (2006) 1.59
Rheb is a critical regulator of autophagy during myocardial ischemia: pathophysiological implications in obesity and metabolic syndrome. Circulation (2012) 1.56
MiR-143/145 deficiency attenuates the progression of atherosclerosis in Ldlr-/-mice. Thromb Haemost (2014) 1.53
Nephrotoxicity of low-osmolality versus iso-osmolality contrast agents: impact of N-acetylcysteine. Kidney Int (2005) 1.52
Activation or inactivation of cardiac Akt/mTOR signaling diverges physiological from pathological hypertrophy. J Cell Physiol (2008) 1.48
SOCS1 gene transfer accelerates the transition to heart failure through the inhibition of the gp130/JAK/STAT pathway. Cardiovasc Res (2012) 1.48
Mechanism of enhanced cardiac function in mice with hypertrophy induced by overexpressed Akt. J Biol Chem (2003) 1.47
TET2 and CSMD1 genes affect SBP response to hydrochlorothiazide in never-treated essential hypertensives. J Hypertens (2015) 1.43
Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail (2011) 1.40
Physiological myocardial hypertrophy: how and why? Front Biosci (2008) 1.35
MicroRNA and cardiac pathologies. Physiol Genomics (2008) 1.32
Interval training normalizes cardiomyocyte function, diastolic Ca2+ control, and SR Ca2+ release synchronicity in a mouse model of diabetic cardiomyopathy. Circ Res (2009) 1.29
Akt regulates L-type Ca2+ channel activity by modulating Cavalpha1 protein stability. J Cell Biol (2009) 1.28
microRNAs in heart disease: putative novel therapeutic targets? Eur Heart J (2010) 1.27
Transplantation of low dose CD34+KDR+ cells promotes vascular and muscular regeneration in ischemic limbs. FASEB J (2004) 1.27
Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure. Cardiovasc Res (2008) 1.26
Circulating microRNAs and aerobic fitness--the HUNT-Study. PLoS One (2013) 1.20
MicroRNAs in cardiovascular biology and heart disease. Circ Cardiovasc Genet (2009) 1.19
Regulation of cell size and contractile function by AKT in cardiomyocytes. Ann N Y Acad Sci (2004) 1.19
Association study on long-living individuals from Southern Italy identifies rs10491334 in the CAMKIV gene that regulates survival proteins. Rejuvenation Res (2011) 1.17
Induced pluripotent stem cell-derived cardiomyocytes in studies of inherited arrhythmias. J Clin Invest (2013) 1.17
Akt/protein kinase B and endothelial nitric oxide synthase mediate muscular neovascularization induced by tissue kallikrein gene transfer. Circulation (2004) 1.15
AKT participates in endothelial dysfunction in hypertension. Circulation (2004) 1.15
Myocardial sarcoplasmic reticulum Ca2+ ATPase function is increased by aerobic interval training. Eur J Cardiovasc Prev Rehabil (2008) 1.13
Genome-wide analysis of histone marks identifying an epigenetic signature of promoters and enhancers underlying cardiac hypertrophy. Proc Natl Acad Sci U S A (2013) 1.13
Correlations between progression of coronary artery disease and circulating endothelial progenitor cells. FASEB J (2010) 1.10
MicroRNAs control gene expression: importance for cardiac development and pathophysiology. Ann N Y Acad Sci (2008) 1.09
Akt increases sarcoplasmic reticulum Ca2+ cycling by direct phosphorylation of phospholamban at Thr17. J Biol Chem (2009) 1.09
Heart infarct in NOD-SCID mice: therapeutic vasculogenesis by transplantation of human CD34+ cells and low dose CD34+KDR+ cells. FASEB J (2004) 1.09
Aerobic interval training enhances cardiomyocyte contractility and Ca2+ cycling by phosphorylation of CaMKII and Thr-17 of phospholamban. J Mol Cell Cardiol (2007) 1.08
MiR-133a regulates collagen 1A1: potential role of miR-133a in myocardial fibrosis in angiotensin II-dependent hypertension. J Cell Physiol (2012) 1.07
Long noncoding RNA: a new player of heart failure? J Cardiovasc Transl Res (2013) 1.05
MicroRNA-134 as a potential plasma biomarker for the diagnosis of acute pulmonary embolism. J Transl Med (2011) 1.01
Doubly heterozygous LMNA and TTN mutations revealed by exome sequencing in a severe form of dilated cardiomyopathy. Eur J Hum Genet (2013) 1.00
c-Myc oncoprotein: cell cycle-related events and new therapeutic challenges in cancer and cardiovascular diseases. Cell Cycle (2003) 1.00
Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents. FASEB J (2009) 0.95
Opposing roles of Akt and STAT3 in the protection of the maternal heart from peripartum stress. Cardiovasc Res (2014) 0.95
Epigenetics: a new mechanism of regulation of heart failure? Basic Res Cardiol (2013) 0.94
Th1 and Th2 cytokines exert regulatory effects upon islet microvascular areas in the NOD mouse. J Cell Biochem (2002) 0.94
Effects of Akt on cardiac myocytes: location counts. Circ Res (2006) 0.94
Molecular determinants of the physiological adaptation to stress in the cardiomyocyte: a focus on AKT. J Mol Cell Cardiol (2004) 0.94
Efficacy and age-related effects of nitric oxide-releasing aspirin on experimental restenosis. Proc Natl Acad Sci U S A (2002) 0.93
Fatty acid percentage in erythrocyte membranes of atrial flutter/fibrillation patients and controls. J Interv Card Electrophysiol (2010) 0.93
microRNAs in hypertrophy and heart failure. Exp Biol Med (Maywood) (2011) 0.92
Stem cell therapy in heart diseases: a review of selected new perspectives, practical considerations and clinical applications. Curr Cardiol Rev (2011) 0.91
Assessment of the 9p21.3 locus in severity of coronary artery disease in the presence and absence of type 2 diabetes. BMC Med Genet (2013) 0.90
MicroRNA-1 downregulation increases connexin 43 displacement and induces ventricular tachyarrhythmias in rodent hypertrophic hearts. PLoS One (2013) 0.89
Role of microRNAs in haemopoiesis, heart hypertrophy and cancer. Biochem Soc Trans (2008) 0.89
TNF-alpha signal transduction in rat neonatal cardiac myocytes: definition of pathways generating from the TNF-alpha receptor. FASEB J (2002) 0.88
RNA silencing: small RNA-mediated posttranscriptional regulation of mRNA and the implications for heart electropathophysiology. J Cardiovasc Electrophysiol (2008) 0.87
Connexin defects underlie arrhythmogenic right ventricular cardiomyopathy in a novel mouse model. Hum Mol Genet (2013) 0.87
Unexpectedly low mutation rates in beta-myosin heavy chain and cardiac myosin binding protein genes in Italian patients with hypertrophic cardiomyopathy. J Cell Physiol (2011) 0.85
Reliable resequencing of the human dystrophin locus by universal long polymerase chain reaction and massive pyrosequencing. Anal Biochem (2010) 0.85
Human embryonic stem cell-derived cardiomyocytes: inducing strategies. Regen Med (2006) 0.84
Arterial remodeling and atherosclerosis: miRNAs involvement. Vascul Pharmacol (2011) 0.83
p300/cAMP-response-element-binding-protein ('CREB')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A (MEF2A) and thyroid hormone receptor-retinoid X receptor. Biochem J (2003) 0.83
The might of microRNA in mitochondria. Circ Res (2012) 0.82
Heart failure: targeting transcriptional and post-transcriptional control mechanisms of hypertrophy for treatment. Int J Biochem Cell Biol (2008) 0.81
Epigenetics in heart failure. Ann N Y Acad Sci (2010) 0.81
[Continuity of care in heart failure: pilot study of the Tuscany region]. G Ital Cardiol (Rome) (2012) 0.80
Generation of human cardiomyocytes: a differentiation protocol from feeder-free human induced pluripotent stem cells. J Vis Exp (2013) 0.79
The circulating level of FABP3 is an indirect biomarker of microRNA-1. J Am Coll Cardiol (2012) 0.79
Circular RNAs and heart failure: new players for an old disease. Cardiovasc Res (2017) 0.78